CR14629

CR14629 is an investigational small molecule drug candidate currently in preclinical development by Rottapharm Biotech. It is being developed as a disease-modifying osteoarthritis drug (DMOAD) specifically targeting the metabolic phenotype of osteoarthritis (metabolic OA). This form of OA is characterized by the involvement of metabolic syndrome components, such as obesity, dyslipidemia, and insulin resistance, which are thought to drive systemic inflammation and joint tissue degradation. CR14629 aims to address the underlying pathophysiology of this OA subtype to prevent or slow structural joint damage, rather than providing only symptomatic relief. As of early 2024, the specific molecular target of CR14629 has not been publicly disclosed by the developer.